Our current study showed an association of rs1056503 with a
reduced NSCLC risk. Liu et al. did not find that this individual
genotype was associated with glioma risk. In contrast, a three-locus interaction model showed that LIG4 SNP rs1805388 (C4T), XRCC4
SNP rs7734849 (A4T) and SNP rs1056503 (G4T) contributed to
glioma susceptibility.33 A functional analysis of XRCC4 rs1056503
demonstrated that this polymorphism might have played a role in
alternative splicing of mRNA.34 This study suggested that the XRCC4
rs9293337 genotype was associated with NSCLC risk and could be a
novel marker for prevention and anticancer intervention studies.
Further study is needed to explore the clinical significance of
rs9293337 in NSCLC patients